Catalyst · readout
Topline data from SURMOUNT-MMOE cardiovascular outcomes trial expected 2025.
Expected: Jan 1, 2025 – Jun 30, 2025
Catalyst details
- Type
- readout
- Status
- pending
- Date precision
- window
- Confidence
- company guidance
- Asset
- Tirzepatide
- Company
- Eli Lilly
Dependencies
- trial-05
Source wording
“Topline data from SURMOUNT-MMOE cardiovascular outcomes trial expected 2025.”
Sources
- registryprimary record
SURMOUNT-4: Tirzepatide after intensive lifestyle intervention
Eli Lilly and Company · ClinicalTrials.gov · Nov 21, 2019 · NCT04159132